Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Astrana Health Expands to 18 Markets, Serving 1.5M Members

Astrana said it has expanded to 18 markets nationwide, up from 17 markets in 2025 and 6 markets in 2023.

The company now says it serves about 1.5 million members, supported by more than 20,000 providers and more than 20 payer partners.

Its operating model is now spread across nine California markets and one market each in Nevada, Arizona, Texas, Georgia, Florida, the DC/Maryland/Virginia region, Hawaii, Rhode Island and Connecticut.

Astrana highlighted several operating metrics tied to its care model:

  • 67% fewer hospital admissions than benchmark
  • 14% shorter inpatient length of stay versus benchmark
  • About 70% of prior authorizations auto-approved instantly

The company also pointed to scale in its provider network, citing 20,000+ providers, and said its AI-native platform includes more than 100 real-time data harmonization capabilities feeding its unified data layer.

In its California example networks, Astrana showed provider counts including 159, 215 and 612 in one market set, and 60, 134 and 710 in another, illustrating the size of its local operating footprint.

The company said its model has been replicated across markets since 2019, when it had 1 market, then 3 in 2020, 3 in 2021, 4 in 2022, 6 in 2023, 6 in 2024, 17 in 2025 and 18 in 2026. Following these announcements, the company's shares moved -4.53%, and are now trading at a price of $33.52. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS